Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis
Lynne A. Murray(AstraZeneca (United Kingdom)), Erica L. Herzog(Yale University), M. Hohmann(Cedars-Sinai Medical Center), Jose D. Herazo‐Maya(University of South Florida), Yang Zhou(Yale University), Darryl A. Knight(University of British Columbia), Jack A. Elias(Brown University), Buqu Hu(Yale University), Matthew A. Sleeman(Aimmune Therapeutics (United Kingdom)), Xueyan Peng(Yale University), Tomas Mustelin(Altimmune (United States)), Ana Lúcia Coelho(Cedars-Sinai Medical Center), David M. Habiel(Cedars-Sinai Medical Center), Meagan W. Moore(Yale University), Bruno Crestani(Inserm), Cory M. Hogaboam(University of Michigan–Ann Arbor), Mridu Gulati, Chun Geun Lee(Yale University), Ana Camelo(Aimmune Therapeutics (United Kingdom)), Changwan Ryu(SleepMed), Huilan Shang(University of Michigan), Awo D. Osafo-Addo(SleepMed)
Cited by 85
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production
|Journal of Clinical Investigation|1999|1.7k
Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2020|1k
Interleukin-13 Induces Tissue Fibrosis by Selectively Stimulating and Activating Transforming Growth Factor β1
|The Journal of Experimental Medicine|2001|926
Plasticity of marrow-derived stem cells
|Blood|2003|830